Sun Pharma recalls multiple eye drops in India over contamination concerns

According to reports, Sun Pharma has recalled multiple eye drop products in India after contamination concerns and has stopped their distribution as a precautionary measure. Experts advise patients not to continue using the affected products or stop treatment without consulting their eye doctor. Eye drop for eyesight/Photo: PixelsAccording to reports, pharmaceutical maker Sun Pharma has recalled multiple eye drop products in India after contamination concerns emerged during manufacturing. The company has also halted the distribution of the affected products and asked distributors across the country to immediately stop supplying them and return all available stock as a precautionary measure.The development came to light after a confidential letter issued by Sun Pharma Distributors Ltd to its distributors, accessed by ANI, instructed them to withdraw several ophthalmic products from the market. The company said it had decided to discontinue further distribution and recall all existing stocks of the affected eye drops available in the distribution channel.The products listed for withdrawal include Depopred 2 ml, Brinolar (BKC Free), Brinzotim Eye Drops 5 ml BKC Free, Lotepred-5 ml, Lotepred 1% Eye Drops, Lotepred LS 0.2%, Lotepred T, Nepalact OD Eye Drops 3 ml, Nepalact-Z, Toba-F and Nepalact Eye Drops 5 ml.According to the communication, distributors have been directed to immediately stop billing the recalled products, provide details of any remaining stock and return all available units, including those received from other sources, on priority. Responding to ANI, a Sun Pharma spokesperson said patient safety remains the company's highest priority. The spokesperson said all necessary steps have been taken in accordance with applicable regulatory requirements and that teams are working to restore the availability of the products so patients continue to have access to appropriate treatment options.The recall has raised concerns among patients who use these medicines for a range of eye conditions, including glaucoma, eye infections, allergies, ocular inflammation and recovery after eye surgery. Since many of these conditions require regular treatment, patients may be worried about whether they should continue using the medicines or stop them immediately. Experts, however, caution against making treatment decisions without consulting an ophthalmologist. According to the report, patients should neither continue using a recalled eye drop nor discontinue treatment on their own. Instead, they should contact their treating eye specialist as soon as possible so that a safe and suitable alternative can be prescribed without interrupting treatment.The report also highlights that maintaining sterility during the manufacturing of eye drops is critical because these medicines are applied directly to the eye. Even suspected contamination at a manufacturing facility can pose a serious risk to patient safety, making product recalls an important precautionary measure.While the recall is precautionary, it serves as a reminder of the importance of strict quality control in the production of ophthalmic medicines. Patients currently using any of the recalled products are advised to check the name of their medication and consult their ophthalmologist before making any changes to their treatment.- EndsPublished By: Smarica PantPublished On: Aug 3, 2026 13:59 IST